NAVITAS-WIND
2.2.2024 16:36:28 CET | Business Wire | Press release
As of February 1, 2024, Executive Partner Maciej Suchy and Executive Partner Adam Bartelik have joined the ownership circle of Navitas Wind A/S. The new co-owners bring solid knowledge and experience from the Renewable energy sector, thereby increasing Navitas Wind’s momentum in the International market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240202857457/en/
The new ownership group and board of directors of Navitas Wind A/S. From left Maciej Suchy, Rene Kildsgaard, Martin Jacobsen, Kuno jacobsen, Glenn Aagesen and Adam Bartelik. (Photo: Business Wire)
Kuno Jacobsen, CEO of Navitas Wind A/S:
“Since our Start in 2019, we have devoted many internal resources to creating a robust foundation for Navitas Wind. Within the management team, we have focused on developing an organization with a strong, industrious drive and a professional mindset – for both customers and employees. Now we enter Navitas’ fifth year of existence and continue our growth journey together with Maciej and Adam. This will enable us, among other things, to develop the company’s competencies, expand our business area, and focus even more on international projects.”
Internationally Experienced Individuals from the Industry:
Short about Maciej Suchy
Extensive operational and commercial experience within the Wind Energy Sector, specialising in construction project management, sales, and business development and people management.
Maciej says: “I feel extremely lucky, thrilled and excited to join this enthusiastic organisation, where the Quality Service is achieved through an innovative Fun&Work approach. Where the PROUD and HAPPY team can only focus on delivering their BEST to the Customers’ satis- faction. How cool is that..? With humble respect, I am committed to doing my best in growing further the Navitas Company with all new innovative projects.”
Short about Adam Bartelik
Extensive operational and project engineering experience within the Wind Energy Sector, specialising in construction project management, new concepts development and people management.
Adam says: ”Passion, and challenges, not an easy business, can only be done with people with the same vision. Creating, developing and constantly improving the company so that everyone is proud to be part of it. This is what motivates me to work with Navitas with friends on a private and professional level. I can’t wait to help develop a company that meets the customer’s needs and is an ideal place to work for our employees. Let’s move to the next level.”
Navitas’s strategic decision to onboard Maciej and Adam is an important milestone in fortifying our corporate capabilities. It is essential for moving the company into its next phase of development. Our objective is to broaden our geographical reach and broaden the range of solutions we offer to our clients, positioning Navitas as an all-in-one hub, turn-key supplier, in the Renewable Energy sector.
Both Maciej and Adam bring a dynamic blend of drive and expertise, pivotal in supporting our ambitious journey. Their involvement in the strategic planning process, ensuring Navitas’s sustained growth and solidifying our position in the market.
The energy sector is facing a crucial industrialization phase internationally.
At Navitas, we believe that our efforts to integrate advanced technology and sustainable methods will be key to achieving a more sustainable future. By securing the future growth of Navitas Wind A/S and maintaining our high-quality level in the wind industry, we confidently move into a new and exciting phase of the company growth.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240202857457/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom